Buy Or Sell Opportunity • Jul 21
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 19% to CN¥49.20. The fair value is estimated to be CN¥62.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.4% over the last 3 years. Earnings per share has grown by 5.1%. Revenue is forecast to grow by 23% in a year. Earnings are forecast to grow by 3.3% in the next year. Announcement • Jun 30
Nanjing Vishee Medical Technology Co., Ltd to Report First Half, 2026 Results on Aug 26, 2026 Nanjing Vishee Medical Technology Co., Ltd announced that they will report first half, 2026 results on Aug 26, 2026 Declared Dividend • Jun 15
Dividend increased to CN¥1.08 Dividend of CN¥1.08 is 35% higher than last year. Ex-date: 18th June 2026 Payment date: 18th June 2026 Dividend yield will be 2.0%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (6% earnings payout ratio) but not covered by cash flows (165% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 8.1% over the next year, which should provide support to the dividend and adequate earnings cover. New Risk • May 31
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company. Reported Earnings • Apr 29
First quarter 2026 earnings released: EPS: CN¥0.64 (vs CN¥0.35 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.64 (up from CN¥0.35 in 1Q 2025). Revenue: CN¥106.0m (up 11% from 1Q 2025). Net income: CN¥61.6m (up 85% from 1Q 2025). Profit margin: 58% (up from 35% in 1Q 2025). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 4% per year. Announcement • Apr 28
Nanjing Vishee Medical Technology Co., Ltd, Annual General Meeting, May 20, 2026 Nanjing Vishee Medical Technology Co., Ltd, Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Nanjing, Jiangsu China Buy Or Sell Opportunity • Apr 14
Now 21% overvalued Over the last 90 days, the stock has fallen 11% to CN¥59.76. The fair value is estimated to be CN¥49.39, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has grown by 3.5%. Revenue is forecast to grow by 42% in 2 years. Earnings are forecast to grow by 39% in the next 2 years. Announcement • Mar 30
Nanjing Vishee Medical Technology Co., Ltd to Report Q1, 2026 Results on Apr 28, 2026 Nanjing Vishee Medical Technology Co., Ltd announced that they will report Q1, 2026 results on Apr 28, 2026 Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥62.50, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 25x in the Medical Equipment industry in China. Total returns to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥50.46 per share. Buy Or Sell Opportunity • Feb 27
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 29% to CN¥58.54. The fair value is estimated to be CN¥47.09, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 47% in the next 2 years. Buy Or Sell Opportunity • Feb 03
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 10% to CN¥56.13. The fair value is estimated to be CN¥46.35, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 47% in the next 2 years. New Risk • Jan 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (133% cash payout ratio). Share price has been volatile over the past 3 months (7.6% average weekly change). Buy Or Sell Opportunity • Jan 05
Now 27% overvalued after recent price rise Over the last 90 days, the stock has risen 17% to CN¥58.08. The fair value is estimated to be CN¥45.90, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 46% in 2 years. Earnings are forecast to grow by 43% in the next 2 years. Announcement • Dec 26
Nanjing Vishee Medical Technology Co., Ltd to Report Fiscal Year 2025 Results on Apr 28, 2026 Nanjing Vishee Medical Technology Co., Ltd announced that they will report fiscal year 2025 results on Apr 28, 2026 Valuation Update With 7 Day Price Move • Oct 30
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥53.99, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 26x in the Medical Equipment industry in China. Total returns to shareholders of 35% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥42.79 per share. Buy Or Sell Opportunity • Oct 27
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 15% to CN¥52.68. The fair value is estimated to be CN¥42.77, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 46% in 2 years. Earnings are forecast to grow by 48% in the next 2 years. Reported Earnings • Oct 23
Third quarter 2025 earnings released: EPS: CN¥0.35 (vs CN¥0.30 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.35 (up from CN¥0.30 in 3Q 2024). Revenue: CN¥115.1m (up 15% from 3Q 2024). Net income: CN¥32.8m (up 15% from 3Q 2024). Profit margin: 28% (in line with 3Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 4% per year. Announcement • Sep 30
Nanjing Vishee Medical Technology Co., Ltd to Report Q3, 2025 Results on Oct 23, 2025 Nanjing Vishee Medical Technology Co., Ltd announced that they will report Q3, 2025 results on Oct 23, 2025 Buy Or Sell Opportunity • Sep 08
Now 25% overvalued after recent price rise Over the last 90 days, the stock has risen 12% to CN¥53.92. The fair value is estimated to be CN¥43.30, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years. Earnings per share has declined by 4.1%. Revenue is forecast to grow by 50% in 2 years. Earnings are forecast to grow by 55% in the next 2 years. Valuation Update With 7 Day Price Move • Aug 07
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥53.55, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 26x in the Medical Equipment industry in China. Total returns to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥38.74 per share. Buy Or Sell Opportunity • Jul 30
Now 21% overvalued Over the last 90 days, the stock has fallen 9.4% to CN¥46.57. The fair value is estimated to be CN¥38.54, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Earnings per share has declined by 8.5%. Revenue is forecast to grow by 48% in 2 years. Earnings are forecast to grow by 57% in the next 2 years. Buy Or Sell Opportunity • Jul 04
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 3.5% to CN¥46.35. The fair value is estimated to be CN¥38.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Earnings per share has declined by 8.5%. Revenue is forecast to grow by 48% in 2 years. Earnings are forecast to grow by 57% in the next 2 years. Announcement • Jun 30
Nanjing Vishee Medical Technology Co., Ltd to Report First Half, 2025 Results on Aug 28, 2025 Nanjing Vishee Medical Technology Co., Ltd announced that they will report first half, 2025 results on Aug 28, 2025 Declared Dividend • Jun 12
Dividend of CN¥0.80 announced Shareholders will receive a dividend of CN¥0.80. Ex-date: 17th June 2025 Payment date: 17th June 2025 Dividend yield will be 1.7%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (67% earnings payout ratio) but not covered by cash flows (267% cash payout ratio). The dividend has increased by an average of 1.6% per year over the past 4 years. However, payments have been volatile during that time. EPS is expected to grow by 81% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Valuation Update With 7 Day Price Move • May 01
Investor sentiment improves as stock rises 37% After last week's 37% share price gain to CN¥51.38, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 21x in the Medical Equipment industry in China. Total returns to shareholders of 55% over the past three years. Reported Earnings • Apr 25
First quarter 2025 earnings released: EPS: CN¥0.35 (vs CN¥0.23 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.35 (up from CN¥0.23 in 1Q 2024). Revenue: CN¥95.9m (up 9.4% from 1Q 2024). Net income: CN¥33.2m (up 53% from 1Q 2024). Profit margin: 35% (up from 25% in 1Q 2024). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Announcement • Apr 25
Nanjing Vishee Medical Technology Co., Ltd, Annual General Meeting, May 16, 2025 Nanjing Vishee Medical Technology Co., Ltd, Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Nanjing, Jiangsu China New Risk • Apr 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 91% Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change). Valuation Update With 7 Day Price Move • Apr 02
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥41.04, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 20x in the Medical Equipment industry in China. Negligible returns to shareholders over past three years. Announcement • Mar 28
Nanjing Vishee Medical Technology Co., Ltd to Report Q1, 2025 Results on Apr 25, 2025 Nanjing Vishee Medical Technology Co., Ltd announced that they will report Q1, 2025 results on Apr 25, 2025 Reported Earnings • Feb 27
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥1.05 (down from CN¥1.43 in FY 2023). Revenue: CN¥400.1m (down 13% from FY 2023). Net income: CN¥100.0m (down 27% from FY 2023). Profit margin: 25% (down from 30% in FY 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 32%. Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 18% per year. Valuation Update With 7 Day Price Move • Feb 25
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥34.82, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Medical Equipment industry in China. Total loss to shareholders of 39% over the past three years. Announcement • Dec 27
Nanjing Vishee Medical Technology Co., Ltd to Report Fiscal Year 2024 Results on Apr 25, 2025 Nanjing Vishee Medical Technology Co., Ltd announced that they will report fiscal year 2024 results on Apr 25, 2025 Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥33.52, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 20x in the Medical Equipment industry in China. Total loss to shareholders of 52% over the past three years. Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.33 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.30 (down from CN¥0.33 in 3Q 2023). Revenue: CN¥100.2m (down 11% from 3Q 2023). Net income: CN¥28.5m (down 8.3% from 3Q 2023). Profit margin: 28% (in line with 3Q 2023). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥26.42, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 59% over the past three years. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.4% average weekly change). Announcement • Sep 30
Nanjing Vishee Medical Technology Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024 Nanjing Vishee Medical Technology Co., Ltd announced that they will report Q3, 2024 results on Oct 25, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥25.35, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 18x in the Medical Equipment industry in China. Total loss to shareholders of 60% over the past three years. Announcement • Jun 28
Nanjing Vishee Medical Technology Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024 Nanjing Vishee Medical Technology Co., Ltd announced that they will report first half, 2024 results on Aug 29, 2024 Buy Or Sell Opportunity • Jun 04
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 38% to CN¥31.42. The fair value is estimated to be CN¥40.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 13%. Revenue is forecast to grow by 60% in 2 years. Earnings are forecast to grow by 70% in the next 2 years. Announcement • Apr 27
Nanjing Vishee Medical Technology Co., Ltd, Annual General Meeting, May 16, 2024 Nanjing Vishee Medical Technology Co., Ltd, Annual General Meeting, May 16, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Nanjing, Jiangsu China Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.32 (vs CN¥0.44 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.32 (down from CN¥0.44 in 1Q 2023). Revenue: CN¥87.7m (down 8.2% from 1Q 2023). Net income: CN¥21.8m (down 28% from 1Q 2023). Profit margin: 25% (down from 32% in 1Q 2023). Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings. Announcement • Mar 30
Nanjing Vishee Medical Technology Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024 Nanjing Vishee Medical Technology Co., Ltd announced that they will report Q1, 2024 results on Apr 26, 2024 Reported Earnings • Feb 27
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥2.00 (up from CN¥1.37 in FY 2022). Revenue: CN¥462.2m (up 44% from FY 2022). Net income: CN¥136.4m (up 45% from FY 2022). Profit margin: 30% (in line with FY 2022). Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 8.4%. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥42.73, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥29.12 per share. Announcement • Nov 11
Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) announces an Equity Buyback for CNY 40 million worth of its shares. Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) announces a share repurchase program. Under the program, the company will repurchase CNY 40 million worth of its shares. The shares will be repurchased at a price of not more than CNY 90 per share. The shares purchased will be used for equity incentive or to convert the corporate bonds issued by the listed company to convertible stocks. The program is valid for 12 months. Reported Earnings • Oct 26
Third quarter 2023 earnings released: EPS: CN¥0.46 (vs CN¥0.35 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.46 (up from CN¥0.35 in 3Q 2022). Revenue: CN¥112.0m (up 36% from 3Q 2022). Net income: CN¥31.1m (up 30% from 3Q 2022). Profit margin: 28% (down from 29% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.31 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.59 (up from CN¥0.31 in 2Q 2022). Revenue: CN¥124.3m (up 55% from 2Q 2022). Net income: CN¥40.5m (up 91% from 2Q 2022). Profit margin: 33% (up from 27% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings. Announcement • Jun 28
Nanjing Vishee Medical Technology Co., Ltd to Report First Half, 2023 Results on Aug 29, 2023 Nanjing Vishee Medical Technology Co., Ltd announced that they will report first half, 2023 results on Aug 29, 2023 Valuation Update With 7 Day Price Move • May 02
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to CN¥79.79, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 26x in the Medical Equipment industry in China. Total returns to shareholders of 65% over the past year. Reported Earnings • Apr 26
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥1.37 (down from CN¥2.60 in FY 2021). Revenue: CN¥321.6m (down 25% from FY 2021). Net income: CN¥93.8m (down 47% from FY 2021). Profit margin: 29% (down from 41% in FY 2021). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 8.7%. Earnings per share (EPS) also missed analyst estimates by 30%. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in China. Major Estimate Revision • Mar 03
Consensus EPS estimates fall by 15%, revenue upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from CN¥447.3m to CN¥475.0m. EPS estimate fell from CN¥2.77 to CN¥2.34 per share. Net income forecast to grow 35% next year vs 37% growth forecast for Medical Equipment industry in China. Consensus price target of CN¥68.00 unchanged from last update. Share price fell 3.6% to CN¥63.08 over the past week. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥69.08, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 26x in the Medical Equipment industry in China. Total loss to shareholders of 23% over the past year. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Nov 04
Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) agreed to acquire a 70% stake in Hefei Hans Curestar Laser Device Co., Ltd. from Wang Bizhan, Huang Heng, Yang Aichun and Xu Qingfen for CNY 58.8 million. Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) agreed to acquire a 70% stake in Hefei Hans Curestar Laser Device Co., Ltd. from Wang Bizhan, Huang Heng, Yang Aichun and Xu Qingfen for CNY 58.8 million on October 31, 2022. Nanjing Vishee Medical Technology will pay consideration from own funds. For the period September 30, 2022, Hefei Hans had CNY 17.61 million of net assets and CNY 22.80 million total assets. Reported Earnings • Oct 31
Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.56 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.35 (down from CN¥0.56 in 3Q 2021). Revenue: CN¥82.5m (down 26% from 3Q 2021). Net income: CN¥23.9m (down 38% from 3Q 2021). Profit margin: 29% (down from 34% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improved over the past week After last week's 24% share price gain to CN¥62.50, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 26x in the Medical Equipment industry in China. Total loss to shareholders of 33% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥32.21 per share. Valuation Update With 7 Day Price Move • Oct 03
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥50.80, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 23x in the Medical Equipment industry in China. Total loss to shareholders of 46% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥35.03 per share. Reported Earnings • Aug 29
Second quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.55 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.31 (down from CN¥0.55 in 2Q 2021). Revenue: CN¥80.0m (down 28% from 2Q 2021). Net income: CN¥21.2m (down 44% from 2Q 2021). Profit margin: 27% (down from 34% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 61%, compared to a 27% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥61.73, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 23x in the Medical Equipment industry in China. Total loss to shareholders of 61% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥35.18 per share. Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥54.18, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 22x in the Medical Equipment industry in China. Total loss to shareholders of 61% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥28.68 per share. Reported Earnings • Apr 28
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint First quarter 2022 results: EPS: CN¥0.25 (down from CN¥0.46 in 1Q 2021). Revenue: CN¥54.1m (down 33% from 1Q 2021). Net income: CN¥17.0m (down 46% from 1Q 2021). Profit margin: 31% (down from 39% in 1Q 2021). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 12%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 40%, compared to a 26% growth forecast for the industry in China. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Apr 12
Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) announces an Equity Buyback for CNY 40 million worth of its shares. Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) announces a share repurchase program. Under the program, the company will repurchase CNY 40 million worth of its shares. The shares will be repurchased at a price of not more than CNY 100 per share. The shares purchased will be used for equity incentive. The program is valid for 12 months. Major Estimate Revision • Jan 28
Consensus revenue estimates fall by 13% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥635.0m to CN¥552.6m. EPS estimate fell from CN¥3.55 to CN¥3.44 per share. Net income forecast to grow 32% next year vs 32% growth forecast for Medical Equipment industry in China. Consensus price target of CN¥150 unchanged from last update. Share price fell 3.4% to CN¥91.60 over the past week. Reported Earnings • Jan 23
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: CN¥2.60 (up from CN¥2.46 in FY 2020). Revenue: CN¥430.0m (up 14% from FY 2020). Net income: CN¥177.9m (up 24% from FY 2020). Profit margin: 41% (up from 38% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 12%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 48%, compared to a 23% growth forecast for the industry in China. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.51 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥111.9m (up 14% from 3Q 2020). Net income: CN¥38.4m (up 20% from 3Q 2020). Profit margin: 34% (up from 33% in 3Q 2020). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Jul 16
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥133, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 41x in the Medical Equipment industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥60.04 per share. Valuation Update With 7 Day Price Move • Jun 23
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥161, the stock trades at a forward P/E ratio of 58x. Average forward P/E is 39x in the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • May 30
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥141, the stock trades at a forward P/E ratio of 53x. Average forward P/E is 38x in the Medical Equipment industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥60.07 per share. Valuation Update With 7 Day Price Move • May 14
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥133, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 38x in the Medical Equipment industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥60.14 per share. Valuation Update With 7 Day Price Move • Apr 26
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥132, the stock trades at a forward P/E ratio of 58x. Average forward P/E is 37x in the Medical Equipment industry in China. Reported Earnings • Apr 11
Full year 2020 earnings released: EPS CN¥2.46 (vs CN¥1.95 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥378.4m (up 19% from FY 2019). Net income: CN¥143.7m (up 44% from FY 2019). Profit margin: 38% (up from 31% in FY 2019). The increase in margin was driven by higher revenue. Is New 90 Day High Low • Feb 23
New 90-day high: CN¥121 The company is up 17% from its price of CN¥103 on 25 November 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥20.14 per share. Valuation Update With 7 Day Price Move • Feb 23
Investor sentiment improved over the past week After last week's 24% share price gain to CN¥121, the stock is trading at a trailing P/E ratio of 56.5x, up from the previous P/E ratio of 45.5x. This compares to an average P/E of 42x in the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥105, the stock is trading at a trailing P/E ratio of 49.3x, up from the previous P/E ratio of 41.9x. This compares to an average P/E of 44x in the Medical Equipment industry in China. Is New 90 Day High Low • Dec 28
New 90-day low: CN¥89.35 The company is down 46% from its price of CN¥164 on 29 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.66 per share. Is New 90 Day High Low • Dec 09
New 90-day low: CN¥98.30 The company is down 40% from its price of CN¥163 on 10 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥16.99 per share. Is New 90 Day High Low • Nov 12
New 90-day low: CN¥114 The company is down 41% from its price of CN¥195 on 14 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥21.19 per share. Valuation Update With 7 Day Price Move • Oct 29
Market pulls back on stock over the past week After last week's 23% share price decline to CN¥126, the stock is trading at a trailing P/E ratio of 58.6x, down from the previous P/E ratio of 75.7x. This compares to an average P/E of 53x in the Medical Equipment industry in China. Is New 90 Day High Low • Oct 25
New 90-day low: CN¥156 The company is down 1.0% from its price of CN¥159 on 27 July 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥21.70 per share. Announcement • Jul 31
Nanjing Vishee Medical Technology Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020 Nanjing Vishee Medical Technology Co., Ltd announced that they will report first half, 2020 results on Aug 26, 2020 
